{"DataElement":{"publicId":"4993835","version":"1","preferredName":"Corticosteroid Evaluation Interval Administered Type","preferredDefinition":"Text term that represents the kind of corticosteroids being given during the evaluation period.","longName":"CORT_EVAL_ADM_TP","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"4993833","version":"1","preferredName":"Corticosteroid Evaluation Interval Timepoint Administered","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI)_The period of time during which an evaluation was performed._A specific point in the time continuum, including those established relative to an event._The act of having given something (e.g., a medication or test).","longName":"2452713v1.0:4993831v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"2452713","version":"1","preferredName":"Corticosteroid","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI)","longName":"C2322","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D052842-7E94-4FD3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4993831","version":"1","preferredName":"Evaluation Interval Timepoint Administered","preferredDefinition":"The period of time during which an evaluation was performed.:A specific point in the time continuum, including those established relative to an event.:The act of having given something (e.g., a medication or test).","longName":"C82534:C68568:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Evaluation Interval","conceptCode":"C82534","definition":"The period of time during which an evaluation was performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Timepoint","conceptCode":"C68568","definition":"A specific point in the time continuum, including those established relative to an event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA2D170-43CD-30AF-E050-BB89AD434C1C","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"ONEDATA","dateModified":"2015-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA2D170-43DE-30AF-E050-BB89AD434C1C","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for ABTC-1403 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2958250","version":"1","preferredName":"Corticosteroid Type","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation)._Type; a subdivision of a particular kind of thing.","longName":"CORT_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"8223B6A1-9823-C0E8-E040-BB89AD43538F","beginDate":"2009-11-05","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"ONEDATA","dateModified":"2010-03-19","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2839905","version":"1","preferredName":"Other","longName":"2839905","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"635B8107-2331-1337-E040-BB89AD432C60","latestVersionIndicator":"Yes","beginDate":"2009-02-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A5BE05-438F-2754-E040-BB89AD435329","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A5BE05-4399-2754-E040-BB89AD435329","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"Methylprednisolone","valueDescription":"Methylprednisolone","ValueMeaning":{"publicId":"2578269","version":"1","preferredName":"Methylprednisolone","longName":"2578269","preferredDefinition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone","conceptCode":"C647","definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77A5BE05-43A3-2754-E040-BB89AD435329","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"ONEDATA","dateModified":"2009-11-05","deletedIndicator":"No"},{"value":"Beclomethasone","valueDescription":null,"ValueMeaning":{"publicId":"5678498","version":"1","preferredName":"Beclomethasone","longName":"5678498v1.00","preferredDefinition":"The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beclomethasone Dipropionate","conceptCode":"C299","definition":"The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7484-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F44E56-74EC-5C5A-E063-731AD00A89D3","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Budesonide","valueDescription":null,"ValueMeaning":{"publicId":"3305276","version":"1","preferredName":"Budesonide","longName":"3305276","preferredDefinition":"A glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Budesonide","conceptCode":"C1027","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1A4B8-0D5C-8518-E040-BB89AD435A01","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F44E56-74ED-5C5A-E063-731AD00A89D3","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"None","valueDescription":null,"ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F8947F-DB8E-2116-E063-731AD00A4BA8","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2964507","version":"1","preferredName":"Corticosteroid Type","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI):Type; a subdivision of a particular kind of thing.","longName":"C2322:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"79D8EED5-411A-537A-E040-BB89AD430FA1","latestVersionIndicator":"Yes","beginDate":"2009-12-03","endDate":null,"createdBy":"WHITES","dateCreated":"2009-12-03","modifiedBy":"ONEDATA","dateModified":"2009-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77A5BE05-4372-2754-E040-BB89AD435329","latestVersionIndicator":"Yes","beginDate":"2009-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-05","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":".","administrativeNotes":"2023.8.2 Added PVs per ticket request CADSR0002666. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3335728","version":"1","longName":"Protocols","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4971072","version":"1","longName":"ABTC 1403","context":"ABTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"What corticosteroids were bei","type":"Preferred Question Text","description":"What corticosteroids were being given during this evaluation period?","url":null,"context":"ABTC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA2F730-E974-4D70-E050-BB89AD435A9C","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeDescription":"Created for ABTC-1403 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}